 

Active ingredient: Bismuth Subcitrate Potassium; Metronidazole; Tetracycline 
Hydrochloride 

 

Form/Route: Capsule/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 

Design: Single-dose, two-way crossover in-vivo 

Strength: 140 mg; 125 mg; 125 mg. A dose of 3 capsules is recommended. 

Subjects: Normal healthy males and females, general population. 

Additional Comments: Females should not be pregnant, and if applicable, should practice 
abstention or contraception during the study. 




_____________________________________________________________________________ 

 

2. Type of study: Fed 

Design: Single-dose, two-way crossover in-vivo 

Strength: 140 mg; 125 mg; 125 mg. A dose of 3 capsules is recommended. 

Subjects: Normal healthy males and females, general population. 

Additional Comments: Please see comments above 




_____________________________________________________________________________ 

 

Analytes to measure: Bismuth; Metronidazole; Tetracycline in plasma 

 

Bioequivalence based on (90% CI): Bismuth; Metronidazole; Tetracycline 

 

Waiver request of in-vivo testing: Not Applicable 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this 
product at this website. Please conduct comparative dissolution testing on 12 dosage units each 
of all strengths of the test and reference products. Specifications will be determined upon review 
of the application. 

 


